Development of High-growth African Swine Fever Virus (ASFV) in MA-104 Cells

Duy Tien Do ( duy.dotien@hcmuaf.edu.vn )
Faculty of Animal Sciences and Veterinary Medicine, Nong Lam University  https://orcid.org/0000-0002-1825-2623

Toan Tat Nguyen
Faculty of Animal Sciences and Veterinary Medicine, Nong Lam University

Research Article

Keywords: African swine fever virus, cell lines, MA104, Vietnam

DOI: https://doi.org/10.21203/rs.3.rs-511079/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

The goal of this study was to identify a candidate commercial cell line for the replication of African swine fever virus (ASFV) by comparing several available cell lines with various medium factors. In the sensitivity test of cells, MA104 and MARC-145 had strong potential for ASFV replication. Next, MA104 cells were used to compare the adaptation of ASFV obtained from tissue homogenates and blood samples in various infectious media. At the 10th passage, the ASFV obtained from the blood sample had a significantly higher viral load than that obtained from the tissue sample (P = 0.00), exhibiting a mean Ct value = 20.39 ± 1.99 compared with 25.36 ± 2.11. For blood samples, ASFV grew on infectious medium B more robustly than on infectious medium A (P = 0.006), corresponding to a Ct value = 19.58 ± 2.10 versus 21.20 ± 1.47. ASFV originating from blood specimens continued to multiply gradually and peaked in the 15th passage, exhibiting a Ct value = 14.36 ± 0.22 in infectious medium B and a Ct value = 15.42 ± 0.14 in infectious medium A. However, there was no difference (P = 0.062) in ASFV growth between infectious media A and B when ASFV was cultured from tissue homogenates. In this study, a model was developed to enhance ASFV replication through adaptation to MA104 cells and the lack of mutation in serial culture passages may serve to maintain the immunogenicity of ASFV isolates when they are developed as vaccine candidates.

1. Introduction

African swine fever virus (ASFV) is an enveloped icosahedral double-stranded DNA virus that belongs to the genus Asfivirus and family Asfaviidae [20]. ASFV causes a highly contagious hemorrhagic disease with a high mortality rates in domestic pigs. The virus has been isolated across various cell lines, but identifying a cell line to develop an effective commercial vaccine has been challenging. Although many continuous cell lines, including Vero cells, are used for the propagation and titration of ASFV [9], the virus replicates most freely in a monocyte/macrophage lineage [5–6, 12]. Among the various types of macrophages assessed, pulmonary alveolar macrophages (PAMs) were suggested to be more susceptible to ASFV infection than bone marrow-derived macrophages or blood monocytes [2, 16]. The maturation stage of PAMs, which is relevant to the expression of surface molecules, may contribute to virus entry into the cell [19]. Despite the numerous advantages of PAMs, ethical constraints exist regarding these cells, as it is necessary to harvest large quantities to conduct a study. In addition, it is difficult to obtain consistent phenotypes of macrophages among different animals. Recently, a commercial cell type (MA104) was determined to be highly stable when used for the isolation of clinical samples [15].

In early 2019, ASFV invaded the pig population in northern Vietnam and was identified as genotype II, which was identical to the strain from China [10–11]. According to the history of this disease, pigs in Vietnam suffered the fastest spread of this virus; after only 9 months, 63/63 provinces announced the presence of the virus in pig herds, which caused a heavy damage, threatening the stability of the pig herd in particular and the pork food production sector in general [21]. Therefore, research on the development of vaccines based on the prototype field virus is urgently required, but a major obstacle to effective vaccine development is identifying a commercial cell line that is suitable for high-yield viral replication. The goal of this study was to identify a candidate commercial cell line by comparing the levels of ASFV replication in several available cell lines with various medium factors.

2. Materials And Methods

2.1. Field sample and virus

The blood and visceral tissues of infected sows were collected from a farrow-to-finish, open-house family sow farm in southern Vietnam. The pathology in infected pigs was characteristic of the acute form, which was in keeping with the findings of previous reports [4]. Sows displayed anorexia, redness of skin, and high fever followed by sudden death, and growing pigs also showed clinical signs, including recumbency with a high fever (over 41°C) and dominant redness of skin followed by rapid death. The blood and fresh organ specimens were confirmed to be ASFV-positive by routine PCR, as recommended by the Office International des Epizooties (OIE, Paris, France). The DNA of the infected ASF virus strain was amplified via PCR analyses, and the partial genetic segments encoding p72, p54 and p30 were sequenced using reference primers from previous reports [1, 7, 18], showing that the virus belonged to genotype II, which was entirely homologous to the first identified strain invading the Vietnamese pig population [10]. In addition, the ASF viral sequences were submitted to GenBank (NCBI); they were named D/ASF/POT(TISSUE)/Vietnam/2019, D/ASF/POB(BLOOD)/Vietnam/2019 originating from fresh specimens and D/ASF/P1/Vietnam/2019, D/ASF/P5/Vietnam/2019, D/ASF/P10/Vietnam/2019 and D/ASF/P15/Vietnam/2019 from cultured viruses at passages 1, 5, 10, and 15, which had accession numbers MW451088-92 for genetic sequences encoding p72, MW451094-98 for genetic sequences encoding p54, and MW451106-10 for genetic sequences encoding p30.

2.1. Cells

Cells were grown in Minimum Essential Eagle Medium-alpha modification (α-MEM) supplemented with 5% FBS, 100 U of penicillin/ml, and 100 μg of streptomycin/ml. The cells were cultured in a humidified incubator with 5% CO2 at 37°C. All cells (MA104, MARC-145, Vero, PK-15, PAM and BHK21) were provided by ChoongAng Vaccine Laboratories (CAVAC), Daejeon, 34055, Republic of Korea.

2.2. ASFV isolation and adaptation

MA104 and other cells were inoculated with each of the clinical samples that were ASFV-positive, as determined by RT-PCR, and maintained in our laboratory from 2019 to 2020. The tissue samples, including lung, spleen, and lymph nodes, were homogenized in PBS with 100 U of penicillin/ml and 100 μg of streptomycin/ml, frozen and thawed three times, and then clarified by centrifugation at 12,000 g for 10 min at 4°C. The supernatants were collected, filtered through a 0.22-μm filter, and utilized to inoculate MA104 cells or other cells.

In the first phase, an in vitro experiment was performed to detect ASFV-sensitive cell lines. Blood anticoagulated by EDTA from infected pigs had a Ct value = 20.21 (qPCR) and was used for isolation. Such cell lines as PAM, MARC-145, Vero, PK-15, MA104 and BHK21, described above, were used for the test. A mixing ratio of 50:50 diluted sample liquid and cells (1x106 cell/ml) was employed, and cells were incubated for 3 days in 5% CO2 at 37°C. After that step, the
suspending was inoculated in 10 ml of the growth medium in a 25-ml flask. Infectious media (A and B) and α-MEM were used with individual cell lines to compare the adaptability of ASF viruses. Daily cell observation and viral load were identified by qPCR from 150 µl of the cultured supernatant and infected cells, and cells were subsequently stained to confirm the positivity of ASFV by immunocytochemistry (ICC) on day 7 after infection and incubation (passage 1). Next, the virus in the cultured fluid was subpassaged continuously 2 times (passages 2 and 3) in a similar manner.

After that step, MA104 cells were used to evaluate the progressive adaptation of ASFV. The infectious media (A and B) and two sample types (blood and tissue) from the same diseased sow were used to determine whether ASFV had different responses to the medium composition from different sample sources on MA104. A 50:50 diluted sample liquid and cells (1x106 cell/ml) were mixed and incubated with 5% CO2 at 37°C for 3 days, as described above. Next, the suspension was inoculated in 10 ml of the medium in a 25-ml flask. Daily cell observation and virus identification by qPCR from 150 µl of culture supernatant, as well as staining through ICC, confirmed the positivity of ASF virus at 1, 3, 5 and 7 days. Next, the virus in the cultured fluid was continuously passaged 9 times (passages 2 to 10) in a similar manner.

2.3. Realtime PCR

Detection of viral DNA in the cell culture supernatant was performed to evaluate virus production in the cells. Real-time polymerase chain reaction (qPCR) targeting p72 genes was performed on the infected culture supernatant of the cell line at 7 days postinfection (dpi). The forward and reverse primers and probe were 5'-CTGCTCATGGTATCAATCTTATCGA-3' and 5'- GATACCACAAGATC(AG)GCCGT-3' and 5'-(FAM)-CCACGGGAGGAATACCAACCCAGTG-3'-(TAMRA), respectively [8]. The results are presented as CT values.

2.4. Immunocytochemistry (ICC) staining of cells in culture

Together with the qPCR technique, cells were specifically stained by immunocytochemistry, as previously described with only slight modifications [13], to determine the viral protein expressed by ASFV infection. At 7 dpi and under incubation at 37°C, the infected cells described above were fixed and permeabilized in 80% acetone for 30 min at -20°C. After fixation, immunocytochemistry was performed using commercially available monoclonal antibodies specific for the viral protein p30 (Humimmu, Salem, NH) to detect early protein synthesis.

2.5. Sequencing and genetic analysis in serial passages

DNA was extracted and collected from blood before inoculation into cell culture (P0). Following passages 1 (P1), 5 (P5), 10 (P10), and 15 (P15), viral DNA from culture media was also obtained and subjected to comparative analysis of nucleotide and amino acid sequences through examination of amplified PCR products using reference primers from previous studies [1, 7, 18]. In this analysis, sequences encoding the major structural viral proteins p30, p54 and p72 from passaged, isolated virus samples were amplified, sequenced and analyzed using Mega X software. Bootstrap values were calculated based on 1000 replicates by the neighbor-joining method. The immunogenic proteins p30 and p54 were also further analyzed to determine whether there were any changes in the antigenic regions of ASFV among different passages and references [14, 23].

3. Results

The ASFV used in this study belonged to genotype II (Fig. 3), and the nucleotide and amino acid sequences encoding p72, p54 and p30 in this virus were completely similar to those of the first ASFV isolate previously published in northern Vietnam (Vietnam/Hanoi/2019), which was identified as originating in China.

The inoculation of ASFV into the PAM, MARC-145, Vero, PK15, MA104 and BHK21 cell lines, as monitored through 3 passages, showed that MA104 and MARC-145 have potential for ASF virus replication. With infectious medium B, in MA104 cells, the Ct value of ASF DNA was 23.55, 22.14 and 19.95 at passages 1, 2 and 3, respectively, while in MARC-145 cells, the Ct value of ASF DNA was 25.51, 26.31 and 25.37 at passages 1, 2, and 3, respectively. With infectious medium A, in MA104 cells, the Ct value of ASF DNA was 23.87, 23.06, and 19.24 at passages 1, 2 and 3, respectively, while in MARC-145 cells, the Ct value of ASF DNA was 25.51, 26.31 and 25.37 at passages 1, 2, and 3, respectively. With blood samples, ASFV grew on infectious medium B better than on infectious medium A (P = 0.006), to determine whether ASFV had different responses to the medium composition from different sample sources on MA104. A 50:50 diluted sample liquid and cells (1x106 cell/ml) were mixed and incubated with 5% CO2 at 37°C for 3 days, as described above. Next, the suspension was inoculated in 10 ml of the medium in a 25-ml flask. Daily cell observation and virus identification by qPCR from 150 µl of culture supernatant, as well as staining through ICC, confirmed the positivity of ASF virus at 1, 3, 5 and 7 days. Next, the virus in the cultured fluid was continuously passaged 9 times (passages 2 to 10) in a similar manner.

MA104 cells were used to compare ASFV adaptation from tissue homogenates and blood samples on various infectious media (Fig. 1). At the 10th passage, the ASFV obtained from the blood sample had a significantly higher viral load than that obtained from the tissue sample (P = 0.00), exhibiting a Ct value mean = 20.39 ± 1.99 compared with 25.36 ± 2.11. With blood samples, ASFV grew on infectious medium B better than on infectious medium A (P = 0.006), corresponding to a Ct value = 19.58 ± 2.10 compared to 21.20 ± 1.47, ASFV originating from blood specimens continued to multiply gradually and peaked in the 15th passage with a Ct value = 14.36 ± 0.22 in infectious medium B and a Ct value = 15.42 ± 0.14 in infectious medium A. However, there was no difference (P = 0.062) in ASFV growth between infectious media A and B when cultured from tissue homogenates. The results showed that in MA104 cells, ASFV isolation from blood samples under infectious medium B conditions promoted optimal growth of this virus (black line in Fig. 1, Fig. 2). The nucleotide/amino acid sequences of the sequences encoding the p72, p54 and p30 proteins of the ASFV collected from MA104 cell supernatants through passages P0, P1, P5, P10 and P15 were 100% homologous when aligned. Moreover, antigenic regions in proteins p30 and p54 were highly conserved among the various ASFV culture passages (Table 2).
Table 1
The susceptibility of available cell lines to ASFV in various passages (pass#)

| Media/Passage | PAM | MARC-145 | Vero | PK-15 | MA104 | BHK21 |
|---------------|-----|----------|------|-------|-------|-------|
| Infectious medium B | Pass#1 | na   | 25.51 | na   | 23.55 | na   |
|                | Pass#2 | na   | 26.31 | na   | 22.14 | na   |
|                | Pass#3 | na   | 25.37 | na   | 19.95 | na   |
|                | Mock   | na   | Neg   | na   | Neg   | na   |
| Infectious medium A | Pass#1 | 22.79 | 23.81 | 30.01 | 23.13 | 23.87 |
|                | Pass#2 | 29.19 | 24.71 | 34.43 | 29.34 | 23.06 |
|                | Pass#3 | Neg  | 22.84 | Neg   | 36.02 | 19.24 |
|                | Mock   | Neg  | Neg   | Neg   | Neg   | Neg   |
| α-MEM         | Pass#1 | 26.75 | 30.08 | 33.12 | 25.02 | 28.18 |
|                | Pass#2 | 27.53 | 32.91 | 35.01 | 29.34 | 30.75 |
|                | Pass#3 | Neg  | 36.23 | Neg   | 33.48 | Neg   |
|                | Mock   | Neg  | Neg   | Neg   | Neg   | Neg   |
|                | na, not available |

Table 2
Comparison of the p30 and p54 antigenic regions of the studied ASFVs with those of other reference strains

| Virus strain           | Genotype | p30                     | p54                     |
|------------------------|----------|-------------------------|-------------------------|
| D/ASF/POT/Vietnam/2019 | II       | 61-DIVKSARYAGGYTEHQAQEENMLHVL-90 | 96-ESSASESSENIH-105 |
| D/ASF/POB/Vietnam/2019 | II       | ...                      | ...                      |
| D/ASF/P1/Vietnam/2019  | II       | ...                      | ...                      |
| D/ASF/P5/Vietnam/2019  | II       | ...                      | ...                      |
| D/ASF/P10/Vietnam/2019 | II       | ...                      | ...                      |
| D/ASF/P15/Vietnam/2019 | II       | ...                      | ...                      |
| MK543947/Belgium/Etalle/wb/2018 | II | ...                      | ...                      |
| MK628478/Lithuania/LT14/1490/2014 | II | ...                      | ...                      |
| MT180393/Vietnam/NgheAn/2019 | II | ...                      | ...                      |
| MT166692/Vietnam/Hanoi/2019 | II | ...                      | ...                      |
| MN172368/China/CAS19-01/2019 | II | ...                      | ...                      |
| AM712240/P ortugal/OURT88/3 | I    | ...                      | ...                      |
| MH025916/Uganda/R8/2015 | I    | ...                      | ...                      |

4. Discussion

Previous studies of ASFV isolation used primary pulmonary alveolar macrophage (PAM) cells because of their high adaptation [2, 6, 9, 20]; however, this cell line can only be utilized in research and is not a candidate to grow large amounts of ASF virus for vaccine production due to high costs. In addition, there is also an issue of animal ethics with the large-scale collection of primary cells; meanwhile, several other commercial cell lines exhibit no evidence of stable replication of the ASF virus. Recently, a commercial cell type (MA104) was determined to be highly stable when used for the isolation of clinical samples [15]. Our results in this study appear to be in keeping with the findings of the study by Rai et al., 2020; however, the COVID-19 pandemic interrupted some of the final steps necessary to obtain sufficient scientific information to enable publication. However, it should be noted that the results obtained by our study and previous work [15] demonstrate that MA104 is not only a stable cell line for the isolation of ASFV obtained from field samples but also exhibits strong potential as a candidate cell line for commercial vaccine development.
A notable finding of this study was that in the same MA104 cells, ASFV from various sample sources (blood and tissue) exhibited significant differences in adaptability and replication. In addition, modification of the medium composition in the maintenance and growth medium for the same MA104 cells also affected viral growth over 15 passages. The viral load was calculated via the Ct value of qPCR, and the ICC staining technique used a p30 polyclonal antibody. Therefore, medium components may play essential roles in enhancing the reproduction of the ASF virus in culture cell lines. The results of this study showed that there was gradual adaptation and higher growth of ASFV in the serial subpassage cultures, particularly after the 10th to 15th passages. Interestingly, it was noted in this study that ASFV isolated from blood on MA104 cells exhibited considerably better adaptation up to the 10th passage; in contrast, ASFV isolated from tissue samples exhibited slow adaptation, and it was terminated after the 10th passage.

Other cell lines, such as PAM, MARC-145, Vero and PK15, have been described by previous studies on the adaptive capacity of ASFV [2, 16, 19]. However, according to the results of this study, MA104 cells exhibited the most robust ASFV replication, which was in keeping with the findings of a recent publication [15]. Therefore, further research to determine the best biological properties, MOI, variability, and optimal medium composition for the development of ASFV in MA104 cells may facilitate the development of an effective ASF vaccine. This study developed a model to enhance the adaptation of ASFV to MA104 cells. The adapted virus showed high growth potential, but no mutations occurred in structural proteins (p30, p54, and p72), and no change was observed in the antigenic regions of proteins p30 and p54. This lack of change is important in increasing the probability of maintaining immunogenicity when developing a vaccine candidate.

The evidence of propagation of ASFV in the cells in this study was determined by two methods, quantitative PCR (qPCR) (according to the Ct value) and immunocytochemistry (ICC), and highly homologous results were obtained. Hemadsorption (HA) is often the criterion for determining the presence of ASF virus in assays, but good blood quality for testing is not always available in every laboratory; moreover, some strains of virulent ASFV may not possess erythrocytic adsorption properties [3, 17, 22], and the application of ICC in MA104 cells with clear backgrounds is more effective than employing this technique in primary macrophage cells with peroxidase activity [15].

**Declarations**

**Declaration of Competing Interest**

The authors declare that there is no conflict of interest.

**Acknowledgements**

This work was funded by Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through Animal Disease Management Technology Development Program, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA, Gran no. 11908105). The research was accepted and supported by the Department of Animal Health, Vietnam (DAH) and the Ministry of Education and Training, Vietnam (MOET).

**References**

1. Bastos ADS, Penthith ML, Cruciere C, Edrich JL, Hutchings G, Roge F, Thomson GR (2003) Genotyping field strains of African swine fever virus by partial p72 gene characterisation. Arch. Virol 148: 693-706.
2. Blome S, Gabriel C, Beer M (2013) Pathogenesis of African swine fever in domestic pigs and European wild boar. Virus Res 173: 122-130.
3. Borca MV, O'Donnell V, Holinka LG, Risatti GR, Ramirez-Medina E, Vuono EA, Shi J, Pruitt S, Rai A, Silva E (2020) Deletion of CD2-like gene from the genome of African swine fever virus strain Georgia does not attenuate virulence in Sci. Rep 10: 494.
4. Bui TTN, Bui TAD, Lan NT, Makoto O, Kenji K, Song D, Francisco JS, Le VP (2020) Clinical and Pathological Study of the First Outbreak Cases of African Swine Fever in Vietnam, 2019. Frontier. Vet. Sci 7 (392): 1-7.
5. Colgrove GS, Haelterman EO, Coggins L (1969) Pathogenesis of African swine fever in young pigs. Am. J. Vet. Res.
6. De León P, Bustos MJ, Carrascosa AL (2013) Laboratory methods to study African swine fever virus. Virus Res 173: 168–179.
7. Gallardo C, Mwaengo DM, Macharia JM, Arias M, Taracha EA, Soler A, Bishop RP (2009) Enhanced discrimination of African swine fever virus isolates through nucleotide sequencing of the p54, p72, and pB602L (CVR) genes. Virus genes 38: 85-95.
8. King DP, Reid SM, Hutchings GH, Grierson SS, Wilkinson PJ, Dixon LK, Bastos ADS, Drew TW (2003) Development of a TaqMan® PCR assay with internal amplification control for the detection of African swine fever virus. J. Virol. Methods 107: 53–61.
9. Krug PW, Holinka LG, O'Donnell V, Reese B, Sanford B, Fernandez-Sainz I, Borca MV (2015) The progressive adaptation of a Georgian isolate of African swine fever virus to vero cells leads to a gradual attenuation of virulence in swine corresponding to major modifications of the viral genome. V J 89: 2324-2332.
10. Le VP, Jeong DG, YoonSW, Kwon HM., Trinh TBN, Nguyen TL, Bui TTN, Oh J, KimJB, Cheong KM, Van Tuyen N, BaeE, Vu TTH, Yeom M, Na W, and Song D (2019) Outbreak of African Swine Fever Virus, Vietnam, 2019. Emerg. Infect. Dis 25: 1433-1435.
11. Vietnam Department of Animal Health (DAH) (2019) Technical Report: ASF Situation and Prevention In Vietnam [in Vietnamese]. Ministry of Agriculture and Rural Development (MARD), Hanoi, 02/2019.
12. McCullough KC, Basta S, Knötzig S, Gerber H, Schaffner R, Kim YB, Summerfield A (1999) Intermediate stages in monocyte–macrophage differentiation modulate phenotype and susceptibility to virus infection. Immunol 98: 203.
13. Oura CAL, Powell PP, Parkhouse RME (1998) Detection of African swine fever virus in infected pig tissues by immunocytochemistry and in situ hybridisation. J. Virol. Methods 72: 205-217.
14. Petrovan V, Murgia MV, Wu P, Lowe AD, Jia W, Rowland RRR. (2020) Epitope mapping of African swine fever virus (ASFV) structural protein, p54. Virus. Res 279: 197871.
15. Rai A, Pruitt S, Ramirez-Medina E, Vuono AE, Silva E, Velazquez-Salinas L, Carrillo C, Borca VM, Gladue PD. (2020) Identification of a Continuously Stable and Commercially Available Cell Line for the Identification of Infectious African Swine Fever Virus in Clinical Samples. Viruses 12: 820.
16. Rodriguez F et al. (1996) African swine fever: morphopathology of a viral haemorrhagic disease. Vet. Rec 139: 249–254.
17. Rodriguez JM, Yanez RJ, Almazan F, Vinuela E, Rodriguez JF. (1993) African swine fever virus encodes a CD2 homolog responsible for the adhesion of erythrocytes to infected cells. J. Virol 67: 5312–5320.
18. Rowlands RJ, Michaud V, Heath L, Hutchings G, Oura C, Vosloo W, Dixon LK. (2008) African swine fever virus isolate, Georgia, 2007. Emerg. Infect. Dis 45: 170.
19. Sanchez-Torres C, Gomez-Puertas P, Gomez-del-Moral M, Alonso F, Escribano JM, Ezquerra A, Dominguez J. (2003) Expression of porcine CD163 on monocytes/macrophages correlates with permissiveness to African swine fever infection. Arch. Virol 148: 2307–2323.
20. Sanchez-Vizcaino JM, Laddomada A, Arias ML. (2019) African swine fever virus. Diseases of swine, pp 443-452.
21. Yonlayong W, Duy DT, Roongroje T. (2020) The Future of the Pig Industry After the Introduction of African Swine Fever into Asia. Animal Frontiers, pp 30-37. https://doi.org/10.1093/af/vfaa037.
22. Zsak L, Borca MV, Risatti GR, Zsak A, French RA, Lu Z, Kutish GF, Neillan JG, Callahan JD, Nelson WM. (2005) Preclinical diagnosis of African swine fever in contact-exposed swine by a real-time PCR assay. J. Clin. Microbiol 43: 112–119.
23. Wu P, Lowe AD, Rodriguez YY, Murgia MV, Dodd KA, Rowland RR, Jia W. (2020) Antigenic regions of African swine fever virus phosphoprotein P30. Transbound. Emerg. Dis 2020.

Figures

![Fig 1](image-url)

**Figure 1**

The dynamics of ASFV load (Ct value qPCR) in MA104 cells over various culture passages (Pass#1 to Pass#15). The black curve represents the increase in viral load in several culture passages, presented by decreasing Ct value.
Figure 2

MA104 cells infected and mock infected with ASFV on the infectious medium A (a_mock culture, b_passage 1, c_passage 5, d_passage 10, and e_passage 15 and on the infectious medium B (f_mock culture, g_passage 1, h_passage 5, i_passage 10, and j_passage 15). The presence of the virus was determined by using a monoclonal antibody that detects ASFV protein p30 visualized using an immunoperoxidase assay.
Figure 3

Phylogenetic tree of three nucleotide sequences encoded p30, p54, and p72 of ASFV used for isolation. The red circles represent the ASFV sequences from tissue homogenates and blood prior culture (D/ASF/POT(TISSUE)/VietNam/2019; D/ASF/P0B(BLOOD)/VietNam/2019), and from cultured viruses at passage 1 (D/ASF/P1/Vietnam/2019), 5 (D/ASF/P5/Vietnam/2019), 10 (D/ASF/P10/Vietnam/2019) and 15 (D/ASF/P15/Vietnam/2019).